PMID- 25652178
OWN - NLM
STAT- MEDLINE
DCOM- 20151207
LR  - 20220330
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Linking)
VI  - 46
IP  - 4
DP  - 2015 Apr
TI  - YAP/TAZ for cancer therapy: opportunities and challenges (review).
PG  - 1444-52
LID - 10.3892/ijo.2015.2877 [doi]
AB  - YAP (Yes-associated protein) and its paralog TAZ (transcriptional co-activator 
      with PDZ-binding motif) are the main downstream effectors of the Hippo signaling 
      pathway. This pathway is an evolutionally conserved signal cascade, which plays 
      pivotal roles in organ size control and tumorigenesis from Drosophila to mammals. 
      Functionally, when the Hippo pathway is activated, YAP and TAZ will be 
      sequestered in the cytoplasm and degraded. Conversely, when the Hippo pathway is 
      deactivated, YAP and TAZ will translocate into nucleus and promote transcription 
      of downstream genes by forming complexes with transcription factors, such as 
      transcriptional enhancer factors (TEF; also referred to as TEAD), runt-domain 
      transcription factors (Runx) and others. Most of these transcription factors 
      belong to growth promoting or apoptosis-inhibition genes. It has been reported 
      that the deactivation of the Hippo pathway, as well as up-regulation of YAP and 
      TAZ was observed in many human cancers with a high frequency, which suggests that 
      the Hippo pathway may be a potent target for developing anticancer drugs. In this 
      review, we provide an overview of the Hippo pathway and summarize recent advances 
      with respect to the role of YAP and TAZ in Hippo signaling pathway and cancer 
      development. Furthermore, we describe the opportunities and challenges for 
      exploit YAP and TAZ as potential therapeutic targets in cancer.
FAU - Guo, Liwen
AU  - Guo L
AD  - Department of Surgical Oncology, The 1st Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China.
FAU - Teng, Lisong
AU  - Teng L
AD  - Department of Surgical Oncology, The 1st Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150205
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Phosphoproteins)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcription Factors)
RN  - 0 (Transcriptional Coactivator with PDZ-Binding Motif Proteins)
RN  - 0 (WWTR1 protein, human)
RN  - 0 (YAP-Signaling Proteins)
RN  - 0 (YAP1 protein, human)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing/*metabolism
MH  - Animals
MH  - Antineoplastic Agents/*therapeutic use
MH  - Cell Nucleus/metabolism
MH  - Hippo Signaling Pathway
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/*metabolism
MH  - Molecular Targeted Therapy
MH  - Neoplasms/*drug therapy/*metabolism
MH  - Organ Size
MH  - Phosphoproteins/*metabolism
MH  - Protein Serine-Threonine Kinases/metabolism
MH  - *Signal Transduction/drug effects
MH  - Trans-Activators
MH  - Transcription Factors
MH  - Transcriptional Coactivator with PDZ-Binding Motif Proteins
MH  - Up-Regulation/drug effects
MH  - YAP-Signaling Proteins
EDAT- 2015/02/06 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/02/06 06:00
PHST- 2014/12/02 00:00 [received]
PHST- 2015/01/23 00:00 [accepted]
PHST- 2015/02/06 06:00 [entrez]
PHST- 2015/02/06 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.3892/ijo.2015.2877 [doi]
PST - ppublish
SO  - Int J Oncol. 2015 Apr;46(4):1444-52. doi: 10.3892/ijo.2015.2877. Epub 2015 Feb 5.